Investors

The universal condition.
Zero disease-modifying treatments.

Every human who lives past 45 will develop presbyopia. It is the most common age-related disorder on Earth — and no approved therapy addresses its root cause. Lento Bio is changing that.

Scroll
Market Opportunity

A market that grows with the population

Presbyopia is not a disease of lifestyle or genetics — it is a certainty of aging. As global populations grow older, the addressable market expands on a demographic inevitability that no competitor can outgrow.

$19.1B
Global presbyopia treatment market (2024)
Coherent Market Insights
2.1B
People affected by 2030 — up from 1.8 billion today
World Health Organization
$45B
Global reading glasses market — the revenue LB-01 could offset
IMARC Group
~90%
of every person over 45 will need reading glasses — even if they never needed vision correction before.Fricke et al., Ophthalmology (2018)
Why We Stand Out

A fundamentally different approach

Today's options for presbyopia either manage the symptom or work around it entirely. LB-01 is the only approach in development designed to restore the lens itself — addressing the root cause of the condition.

Corrective LensesCurrent PharmaLB-01
Mechanism— External optical aid— Pupil constriction (miosis)✦ Lens flexibility restoration
Side effects— Surface irritation (contacts), peripheral distortion & fall risk (progressives)✕ Headache, dim vision, eye redness, night vision loss✦ Expected to be minimal
Convenience✕ Must carry, wear, maintain✕ Indefinite dosing required✦ Cumulative structural effect
Duration— Only while worn✕ Effect lasts for several hours✦ Molecular repair (durable in principle)
Accommodation✕ No — fixed focal distance✕ No — optical workaround✦ Yes — restores natural function
LB-01 is investigational and has not been approved by any regulatory authority. Some assertions in this comparison are based on interpolation from mechanism of action and preclinical data; results in humans may differ.

What about other lens softeners?

1
Lento Bio is the only lens-softening program currently in development with public preclinical data, (ARVO 2024).
2
LB-01 outperforms LACE, the former clinical asset in the space acquired for $465M in 2016, in three independent assays: in vivo in mice, ex vivo in human lenses, and pharmacokinetics in rabbits.
3
Our approach — a constitutively active monothiol — most closely matches nature's own strategy for maintaining lens clarity: glutathione.
Company History

Major Events & Rounds to Date

April – May 2022
Incorporation and beginning of operations at the Ichor Life Sciences incubator in Potsdam, NY.
September 2022
Completion of $685K pre-seed round led by Ichor Life Sciences.
November 2023
In vivo mouse results confirm LB-01 as lead asset — demonstrating lens-softening activity in a living model.
June 2024
Operations relocated to Ichor Life Sciences' new biotech incubator in Syracuse, NY.
November 2025
Seed Stage A round of ~$2.9M raised to advance LB-01 toward IND-enabling studies.
NYVentures Preseed Innovation Fund · Excell Partners · Upstate Biotech Ventures · Long Run Ventures · Ichor Life Sciences
Our Home

Syracuse, New York

Lento Bio is headquartered in Syracuse, NY as part of the broader Central New York biotech community. We operate within a biotech incubator alongside strategic partner Ichor Life Sciences — giving us access to shared infrastructure, scientific talent, and a collaborative ecosystem purpose-built for early-stage therapeutics development.

The Company

Lento Bio, Inc.

Lento Bio, Inc. is a Delaware C-Corporation founded in 2022, developing LB-01 as a first-in-class topical therapeutic for presbyopia. Currently in IND-enabling studies, the company is led by a team with deep experience in ophthalmic drug development and longevity science.

Get In Touch